1. Health

Promising Results From 3 Investigational COPD Medications

By August 26, 2012

Follow me on:

A lot of buzz is being generated lately by pharmaceutical companies announcing positive results from several new, COPD medications, each of which are in the process of being tested in clinical trials, or have already completed the final phases of study. In fact, in the past week alone, three investigational drugs have been mentioned in the news, each of which show promise in helping people with COPD feel better and live a higher quality of life:

  • MediciNova's MN-221 -- MN-221 is an intravenous, ▀2-adrenergic receptor agonist that is meant to be administered in the emergency room to help reduce admissions to the hospital due to COPD. In Phase II clinical studies, patients in the MN-221 treatment group showed an overall, better improvement of FEV1 than those in the placebo group and those who received only standard, COPD treatment (SOC) alone. Moreover, MN-221 improved respiratory symptoms and improved dyspnea scores by 34% more than SOC alone. Fewer patients were hospitalized in the MN-221 treatment group than in the SOC alone group and when MN-221 was added to standard COPD treatment, there were no significantá safety concerns.
  • GlaskoSmithKline's (GSK) LAMA/LABA combo -- In a recent press release, GSKá and Theravance, Inc. announced completion of Phase III clinical trails involving the investigational combo drug UMEC/VI, containing umeclidinium bromide, a long-acting muscarinic (LAMA) and vilanterol, a long-acting beta agonist (LABA). The once-daily COPD maintenance drug will be delivered using ELLIPTA, a new dry powder inhaler. Results of placebo controlled efficacy studies and active comparator efficacy studies showed that when combined, the two drugs together produced statistically significant improvements in FEV1 compared to each drug individually, a placebo or to tiotropium (Spiriva).
  • Boehringer Ingelheim's olodaterol/tiotropium combo -- In May, 2012, Boehringer Inhelheim announced that clinical studies involving olodaterol, a long-acting ▀2-agonist (LABA) meant to partner with the anticholinergic drug, tiotropium,ásignificantly improved lung function as measured by FEV 1, for at least 24 hours compared to placebo. Phase II studies focused on the impact of different drug-dose combinations in COPD patients while Phase III clinical trials have been completed and the results are being evaluated for presentation at upcoming medical meetings.

How long will it take these drugs to get FDA approval and be available for use in COPD treatment? Read more about the FDA approval process:

[Social Submit this]

Sign up for my free newsletter!
Follow me on Twitter or Facebook

Comments
August 26, 2012 at 8:52 pm
(1) bob s. says:

The iv drug for administration in ER sounds like something which could have saved me a 2 day stay in hospital earlier this month. I actually probably could have left after 2 hours, but it was a sunday and docs wanted to be safe. Down the road maybe this would even be availabel for home use and save trips to er altogther….and probably lots of $$$$ too.

August 27, 2012 at 10:26 am
(2) Dorothy says:

Any new medication which will make a COPD sufferer feel better and have a higher quality of life, will be welcomed with open arms. It’s good to know that this research is going on.

August 27, 2012 at 5:23 pm
(3) don says:

I will be dead before the tests are done.

August 29, 2012 at 6:14 pm
(4) davidgarmon says:

I’m happy to hear any news about new meds,,Thanks Deb,,,,

September 2, 2012 at 11:55 am
(5) gerry mitchell says:

The drug that helps control lung infections sounds like the best on the list. Maybe combined with advair, we would have a winner.

September 29, 2012 at 9:00 am
(6) Pete says:

well , we have heard a lot of stuff for copd that turns out to be just another failure … I do wish they would get a move on

October 12, 2012 at 1:00 pm
(7) harry inkin says:

Hi Debs.Thanks of the news’can you tell me when will it be in the U K Many Thanks Harry Inkin.

February 18, 2013 at 9:16 pm
(8) Patricia Kyle says:

II have been trialing a new drug for COPD I can tell you it is FANTASIC
and I am hoping it will be on the market soon as I have come to the end
of my trial and not looking forward to going back to the normal Spirvia.
We can only hope they hurry up and get it approved !!!!!!!!!

June 13, 2013 at 9:03 pm
(9) Linda says:

what is the name of the fantastic drug?

June 16, 2013 at 1:53 pm
(10) copd says:

I’ve listed the information in the blog post. Please re-visit.

Leave a Comment

Line and paragraph breaks are automatic. Some HTML allowed: <a href="" title="">, <b>, <i>, <strike>

©2014 About.com. All rights reserved.

We comply with the HONcode standard
for trustworthy health
information: verify here.